Apimeds Pharmaceuticals US, Inc. (NYSE: APUS)

Apimeds Pharmaceuticals US, Inc. conducts its business through two wholly-owned operating subsidiaries, Lokahi Therapeutics, Inc. and MindWave Innovations Inc. Lokahi Therapeutics is a clinical stage biopharmaceutical company focused on developing Apitox, a purified pharmaceutical-grade bee venom-based therapy for inflammation and pain management associated with knee osteoarthritis and multiple sclerosis. MindWave Innovations is a technology platform company providing institutional Digital Asset Treasury solutions that enable corporations and institutions to hold, manage, and generate yield on Bitcoin reserves through compliant and scalable infrastructure.

The company generates revenue through the development and potential commercialization of its biopharmaceutical product Apitox, pending regulatory approval, and through its Digital Asset Treasury platform offering services such as treasury management fees, performance and program fees from AI-supported yield programs, validator services, and monetization from ecosystem verticals including ClimateTech, AdTech, and Insurtech.

The company operates through the following segments: Biopharmaceutical Development and Digital Asset Treasury Solutions.

• Biopharmaceutical Development: This segment focuses on the research, development, and potential commercialization of Apitox, a purified bee venom-based therapeutic candidate. Apitox is being developed for the treatment of inflammation and pain management symptoms associated with knee osteoarthritis and multiple sclerosis. The segment leverages prior clinical data from Apimeds Korea’s Apitoxin, which has been marketed and sold in South Korea since 2003 under the brand name Apitoxin for osteoarthritis treatment.

• Digital Asset Treasury Solutions: This segment provides institutional-grade infrastructure for corporate Bitcoin treasury management, including secure wallet architecture, AI-supported yield programs, and a validator-enabled ecosystem. The native token powering governance and utility across this segment’s ecosystem is $NILA. Key offerings include institutional treasury infrastructure, risk-managed yield strategies, and interoperable verticals such as ClimateTech (AQUAE Impact), AdTech (Wave+), and InsurTech (Institutional Insurance Engine).

In the biopharmaceutical sector, the company competes with established pharmaceutical and biotechnology firms developing non-opioid pain and anti-inflammatory therapies, though its Apitox candidate differentiates through a unique mechanism of action derived from bee venom and a history of long-term safety use in South Korea. In the digital asset space, it positions itself as a provider of compliant, institutional-grade Bitcoin treasury solutions, competing with custodians and financial technology firms by offering integrated yield generation, governance via $NILA, and regulatory alignment tailored for institutional clients.

The biopharmaceutical segment targets healthcare providers treating patients with knee osteoarthritis and multiple sclerosis, including rheumatologists, neurologists, and pain management specialists. The Digital Asset Treasury segment serves corporate treasury teams, institutional investors, asset managers, financial institutions, and high-net-worth individuals seeking compliant and scalable solutions for Bitcoin reserve management, yield generation, and governance participation.